General Discussions

Vulnerability Tool Identifies Breast Cancer Survivors at Risk for Functional Decline

By Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
PUBLISHED THURSDAY, JANUARY 1, 1970
Researchers from Case Western Reserve University School of Medicine and the University of Pennsylvania School of Medicine explored the use of the Vulnerable Elders Survey (VES-13) in predicting functional decline and death within 1 year of breast cancer treatment.

The VES-13 has 13 questions about perceptions of health and ability to lift heavy objects, grasp small objects, write, walk a quarter of a mile, work around the house, go shopping, manage money, and perform other activities of independent living. Lower scores indicate higher reported levels of functioning, whereas higher scores suggest declining function.

Participants were aged 65 years or older with newly diagnosed stage I-III breast cancer. They completed the VES-13 at baseline prior to starting neoadjuvant/adjuvant treatment and again at 1 year.

In the group of 206 women enrolled in the study, 34 (22%) functionally declined, and 7 women died. The estimated risk of functional decline/death rose from 23% for women with a VES-13 score of 3 to 76% for those with a VES-13 score of 10.

Researchers concluded that the women with the highest scores on the VES-13 were most likely to experience decline; therefore, the VES-13 may have some clinical utility in identifying women at risk for functional decline. Study findings are available here.
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.